BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 10629052)

  • 1. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains.
    Chen M; Cheng A; Candotti F; Zhou YJ; Hymel A; Fasth A; Notarangelo LD; O'Shea JJ
    Mol Cell Biol; 2000 Feb; 20(3):947-56. PubMed ID: 10629052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.
    Saharinen P; Silvennoinen O
    J Biol Chem; 2002 Dec; 277(49):47954-63. PubMed ID: 12351625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eleven novel JAK3 mutations in patients with severe combined immunodeficiency-including the first patients with mutations in the kinase domain.
    Mella P; Schumacher RF; Cranston T; de Saint Basile G; Savoldi G; Notarangelo LD
    Hum Mutat; 2001 Oct; 18(4):355-6. PubMed ID: 11668621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain.
    Cacalano NA; Migone TS; Bazan F; Hanson EP; Chen M; Candotti F; O'Shea JJ; Johnston JA
    EMBO J; 1999 Mar; 18(6):1549-58. PubMed ID: 10075926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.
    Russell SM; Tayebi N; Nakajima H; Riedy MC; Roberts JL; Aman MJ; Migone TS; Noguchi M; Markert ML; Buckley RH; O'Shea JJ; Leonard WJ
    Science; 1995 Nov; 270(5237):797-800. PubMed ID: 7481768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation.
    Liu KD; Gaffen SL; Goldsmith MA; Greene WC
    Curr Biol; 1997 Nov; 7(11):817-26. PubMed ID: 9382798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and functional basis for JAK3-deficient severe combined immunodeficiency.
    Candotti F; Oakes SA; Johnston JA; Giliani S; Schumacher RF; Mella P; Fiorini M; Ugazio AG; Badolato R; Notarangelo LD; Bozzi F; Macchi P; Strina D; Vezzoni P; Blaese RM; O'Shea JJ; Villa A
    Blood; 1997 Nov; 90(10):3996-4003. PubMed ID: 9354668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular modeling of the Jak3 kinase domains and structural basis for severe combined immunodeficiency.
    Vihinen M; Villa A; Mella P; Schumacher RF; Savoldi G; O'Shea JJ; Candotti F; Notarangelo LD
    Clin Immunol; 2000 Aug; 96(2):108-18. PubMed ID: 10900158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction.
    Candotti F; Oakes SA; Johnston JA; Notarangelo LD; O'Shea JJ; Blaese RM
    J Exp Med; 1996 Jun; 183(6):2687-92. PubMed ID: 8676091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation.
    Roberts JL; Lengi A; Brown SM; Chen M; Zhou YJ; O'Shea JJ; Buckley RH
    Blood; 2004 Mar; 103(6):2009-18. PubMed ID: 14615376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity.
    Zhou YJ; Hanson EP; Chen YQ; Magnuson K; Chen M; Swann PG; Wange RL; Changelian PS; O'Shea JJ
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13850-5. PubMed ID: 9391116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocyte function in a severe combined immunodeficient patient with a donor splice site mutation in the Jak3 gene.
    Villa A; Sironi M; Macchi P; Matteucci C; Notarangelo LD; Vezzoni P; Mantovani A
    Blood; 1996 Aug; 88(3):817-23. PubMed ID: 8704236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases.
    Zhou YJ; Chen M; Cusack NA; Kimmel LH; Magnuson KS; Boyd JG; Lin W; Roberts JL; Lengi A; Buckley RH; Geahlen RL; Candotti F; Gadina M; Changelian PS; O'Shea JJ
    Mol Cell; 2001 Nov; 8(5):959-69. PubMed ID: 11741532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain.
    Saharinen P; Takaluoma K; Silvennoinen O
    Mol Cell Biol; 2000 May; 20(10):3387-95. PubMed ID: 10779328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction of interleukin-2 receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the gamma-c gene.
    Taylor N; Uribe L; Smith S; Jahn T; Kohn DB; Weinberg K
    Blood; 1996 Apr; 87(8):3103-7. PubMed ID: 8605323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unexpected and variable phenotypes in a family with JAK3 deficiency.
    Frucht DM; Gadina M; Jagadeesh GJ; Aksentijevich I; Takada K; Bleesing JJ; Nelson J; Muul LM; Perham G; Morgan G; Gerritsen EJ; Schumacher RF; Mella P; Veys PA; Fleisher TA; Kaminski ER; Notarangelo LD; O'Shea JJ; Candotti F
    Genes Immun; 2001 Dec; 2(8):422-32. PubMed ID: 11781709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals.
    Chen M; Cheng A; Chen YQ; Hymel A; Hanson EP; Kimmel L; Minami Y; Taniguchi T; Changelian PS; O'Shea JJ
    Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6910-5. PubMed ID: 9192665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID.
    Russell SM; Johnston JA; Noguchi M; Kawamura M; Bacon CM; Friedmann M; Berg M; McVicar DW; Witthuhn BA; Silvennoinen O
    Science; 1994 Nov; 266(5187):1042-5. PubMed ID: 7973658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic structure and promoter region of the murine Janus-family tyrosine kinase, Jak3.
    Gurniak CB; Thomis DC; Berg LJ
    DNA Cell Biol; 1997 Jan; 16(1):85-94. PubMed ID: 9022047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired IL-7 signaling may explain a case of atypical JAK3-SCID.
    Li J; Nara H; Rahman M; Juliana FM; Araki A; Asao H
    Cytokine; 2010 Feb; 49(2):221-8. PubMed ID: 19889552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.